Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostratin is a non-tumor-promoting phorbol ester natural product originally isolated from the New Zealand shrub *Pimelea prostrata* and later identified as the active component of the Samoan medicinal plant *Homalanthus nutans* (mamala tree). It acts as a potent activator of protein kinase C (PKC) signaling. Prostratin is primarily investigated as a latency-reversing agent (LRA) for HIV/AIDS eradication (the "shock and kill" or "kick and kill" strategy), where it reactivates latent HIV-1 reservoirs in resting CD4+ T cells while simultaneously downregulating CD4, CXCR4, and CCR5 receptors to prevent new viral entry. Additionally, prostratin has shown preclinical potential in oncology, such as inhibiting myeloid-derived suppressor cells (MDSCs) via PKC delta activation in triple-negative breast cancer and repressing pancreatic tumor growth by disrupting K-Ras-CaM interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prostratin.